Boston, MA 10/13/2014 (wallstreetpr) – A few days back, when US officials found two Ebola infected people in Texas, questions on country’s preparations to take on one of the deadliest diseases of the world started raising. Although US government said that it was prepared for Ebola, but things might not be that easy. As per the information, an Ebola positive person has been found in US. After the news had come out, shares of Ebola drug makers including Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) jumped significantly well.
Insights of the matter:
Quite a few companies in America have come up with Ebola drug, Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) is one such company. Clinical trials are going on, and if everything goes fine, then people will see TKMR’s drug coming out in the market shortly. Everything started recently when a healthcare professional of Texas Presbyterian Hospital was found Ebola positive. When his blood samples were treated in the laboratory of Texas Department of State Health Services, experts declared him Ebola infected. He has been isolated after preliminary tests, and final tests have been just conducted. According to reports, results are still pending, but government of US doesn’t want to take any chance on this level. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) and other companies have increased the speed of various clinical trials in order to take on any emergency situation.
The healthcare professional that was declared Ebola positive, first experienced a low-grade fever on October 10. He tried to take medicines on his own, but was referred for a test when things didn’t improve. Soon reports of Centers for Disease Control revealed that he was Ebola positive. Officials interviewed him in order to know if there was anyone else in his family or friend circle that had similar symptoms. FDA has informed TKMR and other companies to finish trials of their studies as soon as possible. So far, Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) management has not made any comment on this issue.
